{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:59:19Z","timestamp":1770893959089,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.clinthera.2017.05.353","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T16:30:32Z","timestamp":1497976232000},"page":"1360-1370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acetylator Status Impacts Amifampridine Phosphate (Firdapse\u2122) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function"],"prefix":"10.1016","volume":"39","author":[{"given":"Peter E.","family":"Haroldsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zlatko","family":"Sisic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Datt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald G.","family":"Musson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Ingenito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Pt 3","key":"10.1016\/j.clinthera.2017.05.353_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome. A review of 50 cases","volume":"111","author":"O\u2019Neill","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2017.05.353_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","article-title":"Incidence of serum anti-P\/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"147","author":"Motomura","year":"1997","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.clinthera.2017.05.353_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/pgmj.75.887.516","article-title":"Lambert-Eaton myasthenic syndrome","volume":"75","author":"Seneviratne","year":"1999","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clinthera.2017.05.353_bib4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.clinthera.2017.05.353_bib5","first-page":"1413","article-title":"Myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"20","author":"Sanders","year":"2014","journal-title":"Continuum (Minneap Minn)"},{"key":"10.1016\/j.clinthera.2017.05.353_bib6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12035-014-8887-2","article-title":"Synaptic pathophysiology and treatment of lambert-eaton myasthenic syndrome","volume":"52","author":"Tarr","year":"2015","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.clinthera.2017.05.353_bib7","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1185\/03007991003745209","article-title":"Current therapy for Lambert-Eaton myasthenic syndrome: development of 3, 4-diaminopyridine phosphate salt as first-line symptomatic treatment","volume":"26","author":"Quartel","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2017.05.353_bib8","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0022-3565(25)22023-7","article-title":"Effects of 4-aminopyridine and 3, 4-diaminopyridine on transmitter release at the neuromuscular junction","volume":"227","author":"Thomsen","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2017.05.353_bib9","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/(SICI)1097-4598(199809)21:9<1196::AID-MUS11>3.0.CO;2-Q","article-title":"Effect of 3, 4-diaminopyridine on the time course of decay of compound muscle action potential augmentation in the Lambert-Eaton myasthenic syndrome","volume":"21","author":"Maddison","year":"1998","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.clinthera.2017.05.353_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpba.2006.06.007","article-title":"Stability studies of ionised and non-ionised 3, 4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products","volume":"43","author":"Raust","year":"2007","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.clinthera.2017.05.353_bib11","series-title":"Committee for medicinal products for human use summary of positive opinion for ZENAS, International Nonproprietary Name (INN): amifampridine","year":"2009"},{"key":"10.1016\/j.clinthera.2017.05.353_bib12","doi-asserted-by":"crossref","first-page":"e00099","DOI":"10.1002\/prp2.99","article-title":"Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3, 4-diaminopyridine) phosphate","volume":"3","author":"Haroldsen","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.clinthera.2017.05.353_bib13","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.clinthera.2015.05.498","article-title":"Effects of food intake on the relative bioavailability of amifampridine phosphate salt in healthy adults","volume":"37","author":"Haroldsen","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.05.353_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1146\/annurev.pharmtox.37.1.269","article-title":"Molecular mechanisms of genetic polymorphisms of drug metabolism","volume":"37","author":"Meyer","year":"1997","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2017.05.353_bib15","series-title":"Biotransformation and Metabolite Elucidation of Xenobiotics","first-page":"1","article-title":"Human biotransformation","author":"Parkinson","year":"2010"},{"key":"10.1016\/j.clinthera.2017.05.353_bib16","first-page":"581","article-title":"Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals:correlation with phenotypic activity","volume":"57","author":"Cascorbi","year":"1995","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clinthera.2017.05.353_bib17","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/10937400903158383","article-title":"Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity","volume":"12","author":"Walker","year":"2009","journal-title":"J Toxicol Environ Health B Crit Rev"},{"key":"10.1016\/j.clinthera.2017.05.353_bib18","first-page":"683","article-title":"Distribution and concordance of N-acetyl transferase genotype and phenotype in an American population","volume":"8","author":"Gross","year":"1999","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clinthera.2017.05.353_bib19","doi-asserted-by":"crossref","first-page":"e18507","DOI":"10.1371\/journal.pone.0018507","article-title":"Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: A worldwide population survey","volume":"6","author":"Sabbagh","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinthera.2017.05.353_bib20","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","article-title":"The effect of chronic renal failure on drug metabolism and transport","volume":"4","author":"Dreisbach","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2017.05.353_bib21","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.ackd.2010.05.002","article-title":"The aging kidney: physiological changes","volume":"17","author":"Weinstein","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.clinthera.2017.05.353_bib22","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.clinthera.2017.05.353_bib23","unstructured":"FDA Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function - Study Design, Data Analysis, and Impact on Dosing and Labeling. May 1998."},{"key":"10.1016\/j.clinthera.2017.05.353_bib24","unstructured":"Note for guidance on the evaluation of the Pharmacokinetics of Medicinal Product in patients with impaired renal function, European Medicine Agency. Dec 2004."},{"key":"10.1016\/j.clinthera.2017.05.353_bib25","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1570-0232(03)00065-5","article-title":"Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry","volume":"789","author":"Schneider","year":"2003","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2017.05.353_bib26","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/clpt.2008.59","article-title":"Emerging evidence of the impact of kidney disease on drug metabolism and transport","volume":"83","author":"Nolin","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.05.353_bib27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/dmd.109.029991","article-title":"Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure","volume":"38","author":"Dani","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2017.05.353_bib28","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1681\/ASN.2007090974","article-title":"Downregulation of hepatic acetylation of drugs in chronic renal failure","volume":"19","author":"Simard","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2017.05.353_bib29","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/clpt.1993.198","article-title":"Decreased acetylation of isoniazid in chronic renal failure","volume":"54","author":"Kim","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.05.353_bib30","series-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and applications","author":"Rowland","year":"2011"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817306628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817306628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T20:34:33Z","timestamp":1750365273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817306628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0149291817306628"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.05.353","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acetylator Status Impacts Amifampridine Phosphate (Firdapse\u2122) Pharmacokinetics and Exposure to a Greater Extent Than Renal Function","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.05.353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}